Press Release

ACADIA (ACAD) Up on Resubmission Plan for Nuplazid sNDA to FDA

ACADIA (ACAD) Up on Resubmission Plan for Nuplazid sNDA to FDA


ylliX - Online Advertising Network

ACADIA (ACAD) to resubmit sNDA for Nuplazid (pimavanserin) to the FDA for treating hallucinations and delusions associated with dementia focused on Alzheimer’s disease psychosis. Shares rise.

...read full article on Zacks Investment Research